INCWADANA YEENDABA
Ngemibuzo malunga neemveliso zethu okanye uluhlu lwamaxabiso, nceda ushiye i-imeyile yakho kuthi kwaye siya kuqhagamshelana phakathi kweeyure ezingama-24.
BUZA NGOKUImeko yezothutho&ecetyiswayo indlela yokuthumela ngenqanawa:
ngomoya, ngolwandle okanye nge-express
Imeko yokugcina:
umoya ophakathi, Gcina kwisikhenkcisi, ngaphantsi kwe -20°C
Ubuncinci boMyinge woMyalelo:
Uthethathethwano
Isiqinisekiso:
COA, HPLC, GC, HNMR, Assay, Water Content(KF), TLC iyafumaneka
iTyrosine, iNCA;
I-N-Carboxy-L-tyrosine anhydride;
(4S) -4 - [(4-Hydroxyphenyl) methyl] -2,5-oxazolidinedione;
L-Tyrosine N-carboxyanhydride;
(2,5-Oxazolidinedione,4-[(4-hydroxyphenyl)Methyl]-, (4S)-;
I-N-Carbonyl-L-Tyrosine Anhydride
Ngokuqhelekileyo zisetyenziselwa ukupakisha umgubo.Yaye anokuthintela ukukhanya kwelanga namanzi ukuba angabi mabi.
Ibhokisi elukhuni inokukhusela iimveliso zakho ekuqhekekeni kwaye zibe manzi.
3415-08-5 L-Tyr-NCA yenye ye-intermediates ye-Glatiramer Acetate.
I-Glatiramer Acetate yi-agent ye-peptide elungiselelwe ngokwenziwa eyenziwe ngama-amino acids amane: i-glutamic acid, i-alanine, i-tyrosine, kunye ne-lysine.Ukusetyenziswa kwayo okuphambili kunyango lwe-Multiple Sclerosis (MS), isifo esingapheliyo, esivuthayo, esiphazamisayo esichaphazela inkqubo ye-nervous central.Ngokusebenzisa indlela "yokunyanzeliswa kwe-bypass," i-Glatiramer Acetate yenza i-immunomodulatory kunye ne-anti-inflammatory effects kwi-MS, inyusa amanqanaba e-brain-derived neurotrophic factor (BDNF), ukunciphisa ukuvuvukala okubangelwa ukuchithwa kwe-demyelination, kunye nokukhuthaza ukukhula kwee-axons kunye ne-myelin sheaths.
Ehlabathini lonke, i-Glatiramer Acetate ifumene ukusetyenziswa ngokubanzi.Ngokomzekelo, eUnited States, ithengiswa phantsi kwegama le-brand Copaxone kwaye yamkelwe yi-Food and Drug Administration (FDA) kunyango lwe-Multiple Sclerosis.Kumazwe aseNtshona ane-MS ephezulu, ukusebenza kwayo kunye nokunyamezela kuye kwaqatshelwa ngokubanzi.
E-China, nge-28 kaJuni, i-2023, "I-Glatiramer Acetate Injection" ifumene ngokusemthethweni imvume evela kuLawulo lweeMveliso zoNyango lweSizwe (i-NMPA) kunyango lwezigulane zabantu abadala abane-relapsing-remitting Multiple Sclerosis (MS), kuquka i-clinical isolated syndrome, i-relapsing-remitting I-MS, kunye ne-MS eqhubekayo esebenzayo.
L-Gly-NCA | L-Ala-NCA | D-Ala-NCA | L-Val-NCA |
D-Leu-NCA | DL-leu-NCA | L-Phe-NCA | D-Tyr-NCA |
L-Tyr(bzl)-NCA | L-Glu(Obzl)-NCA | I-D-Asp(OBzl)-NCA | L-Lys(tfa)-NCA |
L-Lys(Cbz)-NCA | D-Ls(Cbz)-NCA | Sar-NCA |
1. Inkonzo yeR&D iyafumaneka
2. Umvelisi oqinisekisiweyo we-ISO, isiqinisekiso somgangatho
I-3.Ikhosi epheleleyo yenkonzo yokulandelela ngexesha lemveliso
4.Ixabiso eliphezulu elisebenzayo
5.Amaxwebhu esiqinisekiso somgangatho anikwe ngokwesicelo somthengi
I-6.Inkonzo enkulu emva kokuthengisa, ukugcina ubudlelwane obusondeleyo kunye nomthengi
I-7.Isixhobo esipheleleyo sokunceda ukunciphisa iindleko zokuthumela ngenqanawa
I-8.Isampuli yamahhala enikezelwa ukujonga umgangatho ngaphambi kwayo nayiphi na intlawulo
9.Ixesha lentlawulo ekuxoxwe ngalo
Abathengi be-10.Assit bajongana nemicimbi yaseTshayina